Study wrapper · #940
IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes.
Elmendorf AJ, Yousefian M, Kim IM, et al. Pharmacological research. 2026.
DOI: 10.1016/j.phrs.2025.108077PubMed: 41478576
ReviewMentions: Retatrutide
Editor's note
This IUPHAR review focuses on the mechanistic rationale for glucagon-receptor agonism in metabolic disease, with retatrutide cited as a leading triple agonist. The authors note that the evidence base is largely preclinical rodent data and that human confirmation remains limited. Valuable for mechanism context rather than clinical outcomes.
Plain-language abstract
A mechanistic review of how glucagon-receptor agonism, combined with GLP-1 and GIP agonism in agents like retatrutide, is being studied to increase energy expenditure for weight loss.
Related coverage
Supported
Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis.
BMJ (Clinical research ed.)n=——2026
Weak / none
Effects of retatrutide on learning and memory in streptozotocin-induced male diabetic rats.
Behavioural brain researchn=——2026
Supported
Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
High blood pressure & cardiovascular preventionn=——2026